Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities

Conclusion
Our results suggest a therapeutic strategy for ARID1A-mutated GCs targeting both tumour-intrinsic (BRD4-assocatiated promoter activation) and extrinsic (NFKB immunomodulation) cancer phenotypes.

Source: Gut - August 7, 2023 Category: Gastroenterology Authors: Xu, C., Huang, K. K., Law, J. H., Chua, J. S., Sheng, T., Flores, N. M., Pizzi, M. P., Okabe, A., Tan, A. L. K., Zhu, F., Kumar, V., Lu, X., Benitez, A. M., Lian, B. S. X., Ma, H., Ho, S. W. T., Ramnarayanan, K., Anene-Nzelu, C. G., Razavi-Mohseni, M., Ab Tags: Gut Stomach Source Type: research